HomeCompareKDSKF vs ARCC

KDSKF vs ARCC: Dividend Comparison 2026

KDSKF yields 7.91% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KDSKF wins by $95219.04M in total portfolio value
10 years
KDSKF
KDSKF
● Live price
7.91%
Share price
$25.30
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95219.07M
Annual income
$92,960,025,273.28
Full KDSKF calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — KDSKF vs ARCC

📍 KDSKF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKDSKFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KDSKF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KDSKF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KDSKF
Annual income on $10K today (after 15% tax)
$671.94/yr
After 10yr DRIP, annual income (after tax)
$79,016,021,482.29/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, KDSKF beats the other by $79,016,021,481.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KDSKF + ARCC for your $10,000?

KDSKF: 50%ARCC: 50%
100% ARCC50/50100% KDSKF
Portfolio after 10yr
$47609.55M
Annual income
$46,480,012,637.22/yr
Blended yield
97.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

KDSKF
No analyst data
Altman Z
2.2
Piotroski
7/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KDSKF buys
0
ARCC buys
0
No recent congressional trades found for KDSKF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKDSKFARCC
Forward yield7.91%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%-50%
Portfolio after 10y$95219.07M$24.5K
Annual income after 10y$92,960,025,273.28$1.16
Total dividends collected$95064.75M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: KDSKF vs ARCC ($10,000, DRIP)

YearKDSKF PortfolioKDSKF Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$12,281$1,581.03$11,381$541.15+$900.00KDSKF
2$16,770$3,629.28$12,621$284.08+$4.1KKDSKF
3$27,207$9,263.27$13,827$145.31+$13.4KKDSKF
4$57,202$28,090.61$15,062$73.43+$42.1KKDSKF
5$171,598$110,391.98$16,364$36.89+$155.2KKDSKF
6$802,601$618,990.23$17,757$18.49+$784.8KKDSKF
7$6,270,265$5,411,481.95$19,258$9.25+$6.25MKDSKF
8$85,731,336$79,022,152.83$20,880$4.63+$85.71MKDSKF
9$2,111,255,535$2,019,523,005.66$22,636$2.32+$2111.23MKDSKF
10$95,219,068,696$92,960,025,273.28$24,539$1.16+$95219.04MKDSKF

KDSKF vs ARCC: Complete Analysis 2026

KDSKFStock

Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Nutrition, Materials, and Innovation Center segments. The Nutrition segment offers animal nutrition and health products, including vitamins, premixes, carotenoids, enzymes, microbes, and eubiotics; human nutrition and health products comprising vitamins, nutritional lipids, minerals, carotenoids, nutraceuticals, digestive enzymes, probiotics, and prebiotics, as well as active pharmaceutical ingredients; premix, market-ready solutions, and personalized nutrition; human milk oligosaccharides; and skin and sun care, hair care, and aroma ingredients; omega-3 fatty acids; and specialty food enzymes, cultures, bio-preservation, texturizing hydrocolloids, sugar reduction, and savory taste solutions. The Materials segment provides specialty plastics used in components for the electrical and electronics, automotive, flexible food-packaging, and consumer goods industries; and Dyneema, a fiber solution for use in personal protection, workwear, sports apparel, outdoor equipment, ropes and slings, synthetic chains, and nets for the aquaculture, and renewable energy sectors. The Innovation Center segment offers biomedical materials, and medical device and material manufacturing technologies in the areas of cardiovascular, continence care, dental, diabetes management, gynecology, neurology, ophthalmology, orthopedic, peripheral vascular, plastic and reconstructive surgery, and wound management. It also commercializes yeast technology yeast for ethanol production. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands.

Full KDSKF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this KDSKF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KDSKF vs SCHDKDSKF vs JEPIKDSKF vs OKDSKF vs KOKDSKF vs MAINKDSKF vs HTGCKDSKF vs GBDCKDSKF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.